Authors: Krishnamurthy J; Torrice C; Ramsey MR; Kovalev GI; Al-Regaiey K; Su L; Sharpless NE
Abstract: The Ink4a/Arf locus encodes 2 tumor suppressor molecules, p16INK4a and Arf, which are principal mediators of cellular senescence. To study the links between senescence and aging in vivo, we examined Ink4a/Arf expression in rodent models of aging. We show that expression of p16INK4a and Arf markedly increases in almost all rodent tissues with advancing age, while there is little or no change in the expression of other related cell cycle inhibitors. The increase in expression is restricted to well-defined compartments within each organ studied and occurs in both epithelial and stromal cells of diverse lineages. The age-associated increase in expression of p16INK4a and Arf is attenuated in the kidney, ovary, and heart by caloric restriction, and this decrease correlates with diminished expression of an in vivo marker of senescence, as well as decreased pathology of those organs. Last, the age-related increase in Ink4a/Arf expression can be independently attributed to the expression of Ets-1, a known p16INK4a transcriptional activator, as well as unknown Ink4a/Arf coregulatory molecules. These data suggest that expression of the Ink4a/Arf tumor suppressor locus is a robust biomarker, and possible effector, of mammalian aging.Keywords: ADP-Ribosylation Factor 1/*biosynthesis/genetics; *Aging; Animals; *Biological Markers; Caloric Restriction; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p16/*biosynthesis/genetics; Disease Models, Animal; Humans; Immunohistochemistry; Mice; Models, Biological; Polymerase Chain Reaction; Rats; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tissue Distribution; beta-Galactosidase/metabolism
Journal: The Journal of clinical investigation
Date: Nov. 3, 2004
Select reference article to upload
Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, Sharpless NE (2004) Ink4a/Arf expression is a biomarker of aging. The Journal of clinical investigation 114: 1299-307.